Search Results - "Trivedi, Meghana V"

Metastasis dormancy in estrogen receptor-positive breast cancer by Zhang, Xiang H-F, Giuliano, Mario, Trivedi, Meghana V, Schiff, Rachel, Osborne, C Kent

“…About 20% to 40% of patients with breast cancer eventually develop recurrences in distant organs, which are often not detected until years to decades after the…”
Get full text

Adherence to oral endocrine therapy in racial/ethnic minority patients with low socioeconomic status before and during the COVID-19 pandemic by Rahimi, Sama, Ononogbu, Onyebuchi, Mohan, Anjana, Moussa, Daniel, Abughosh, Susan, Trivedi, Meghana V.

“…Background Adherence to oral endocrine therapy (OET) is crucial in ensuring its maximum benefit in the prevention and treatment of hormone receptor-positive…”
Get full text

The changing role of ER in endocrine resistance by Nardone, Agostina, De Angelis, Carmine, Trivedi, Meghana V, Osborne, C. Kent, Schiff, Rachel

“…Abstract Estrogen receptor (ER) is expressed in approximately 70% of newly diagnosed breast tumors. Although endocrine therapy targeting ER is highly…”
Get full text

Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications by Giuliano, Mario, Trivedi, Meghana V., Schiff, Rachel

“…The estrogen receptor (ER) and/or the human epidermal growth factor receptor 2 (HER2) signaling pathways are the dominant drivers of cell proliferation and…”
Get full text

A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2‐positive breast cancer by Abdulkareem, Noor Mazin, Bhat, Raksha, Qin, Lanfang, Vasaikar, Suhas, Gopinathan, Ambily, Mitchell, Tamika, Shea, Martin J., Nanda, Sarmistha, Thangavel, Hariprasad, Zhang, Bing, De Angelis, Carmine, Schiff, Rachel, Trivedi, Meghana V.

“…While G protein‐coupled receptors (GPCRs) are known to be excellent drug targets, the second largest family of adhesion‐GPCRs is less explored for their role…”
Get full text

NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer by Bhat, Raksha, Thangavel, Hariprasad, Abdulkareem, Noor Mazin, Vasaikar, Suhas, De Angelis, Carmine, Bae, Leon, Cataldo, Maria Letizia, Nanda, Sarmistha, Fu, Xiaoyong, Zhang, Bing, Schiff, Rachel, Trivedi, Meghana V.

“…G Protein-Coupled Receptors (GPCRs) represent the largest superfamily of cell-surface proteins. However, the expression and function of majority of GPCRs…”
Get full text

Biological mechanisms and clinical implications of endocrine resistance in breast cancer by Giuliano, Mario, Schiff, Rachel, Osborne, C. Kent, Trivedi, Meghana V

“…Summary Endocrine therapy represents the first and most efficacious targeted treatment for women with estrogen receptor-positive (ER+) breast cancer. In the…”
Get full text

High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer by Fu, Xiaoyong, Pereira, Resel, Liu, Chia-Chia, De Angelis, Carmine, Shea, Martin J., Nanda, Sarmistha, Qin, Lanfang, Mitchell, Tamika, Cataldo, Maria L., Veeraraghavan, Jamunarani, Sethunath, Vidyalakshmi, Giuliano, Mario, Gutierrez, Carolina, Győrffy, Balázs, Trivedi, Meghana V., Cohen, Ofir, Wagle, Nikhil, Nardone, Agostina, Jeselsohn, Rinath, Rimawi, Mothaffar F., Osborne, C. Kent, Schiff, Rachel

“…Aberrant activation of the forkhead protein FOXA1 is observed in advanced hormone-related cancers. However, the key mediators of high FOXA1 signaling remain…”
Get full text

Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis by Ramirez, Arturo B, Bhat, Raksha, Sahay, Debashish, De Angelis, Carmine, Thangavel, Hariprasad, Hedayatpour, Sina, Dobrolecki, Lacey E, Nardone, Agostina, Giuliano, Mario, Nagi, Chandandeep, Rimawi, Mothaffar, Osborne, C Kent, Lewis, Michael T, Stilwell, Jackie L, Kaldjian, Eric P, Schiff, Rachel, Trivedi, Meghana V

“…Breast cancer patient-derived xenograft (BC-PDX) models represent a continuous and reproducible source of circulating tumor cells (CTCs) for studying their…”
Get full text

Screening of GPCR drugs for repurposing in breast cancer by Abdulkareem, Noor Mazin, Bhat, Raksha, Powell, Reid T, Chikermane, Soumya, Yande, Soham, Trinh, Lisa, Abdelnasser, Hala Y, Tabassum, Mantasha, Ruiz, Alexis, Sobieski, Mary, Nguyen, Nghi D, Park, Jun Hyoung, Johnson, Camille A, Kaipparettu, Benny A, Bond, Richard A, Johnson, Michael, Stephan, Clifford, Trivedi, Meghana V

“…Drug repurposing can overcome both substantial costs and the lengthy process of new drug discovery and development in cancer treatment. Some Food and Drug…”
Get full text

Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis by Giuliano, Mario, Herrera, Sabrina, Christiny, Pavel, Shaw, Chad, Creighton, Chad J, Mitchell, Tamika, Bhat, Raksha, Zhang, Xiaomei, Mao, Sufeng, Dobrolecki, Lacey E, Al-rawi, Ahmed, Chen, Fengju, Veneziani, Bianca M, Zhang, Xiang H-F, Hilsenbeck, Susan G, Contreras, Alejandro, Gutierrez, Carolina, Jeselsohn, Rinath M, Rimawi, Mothaffar F, Osborne, C Kent, Lewis, Michael T, Schiff, Rachel, Trivedi, Meghana V

“…Real-time monitoring of biologic changes in tumors may be possible by investigating the transitional cells such as circulating tumor cells (CTCs) and…”
Get full text

Epigenetic Silencing of THY1 Tracks the Acquisition of the Notch1–EGFR Signaling in a Xenograft Model of CD44+/CD24low/CD90+ Myoepithelial Cells by Montanari, Micaela, Carbone, Maria Rita, Coppola, Luigi, Giuliano, Mario, Arpino, Grazia, Lauria, Rossella, Nardone, Agostina, Leccia, Felicia, Trivedi, Meghana V., Garbi, Corrado, Bianco, Roberto, Avvedimento, Enrico V., De Placido, Sabino, Veneziani, Bianca Maria

“…Abstract The surface glycoprotein THY is a marker of myoepithelial precursor cells, which are basal cells with epithelial–mesenchymal intermediate phenotype…”
Get full text

Comparing the effects of various β-blockers on cardiovascular mortality in breast cancer patients by Tabassum, Mantasha, Chikermane, Soumya G, Johnson, Camille, Abdulkareem, Noor M, Wang, Elisabeth M, Johnson, Michael L, Trivedi, Meghana V

“…Cardiovascular (CV) disease is a leading cause of death in breast cancer (BC) patients due to the increased age and treatments. While individual β-blockers…”
Get full text

Eribulin: A Novel Cytotoxic Chemotherapy Agent by Preston, Jessica N, Trivedi, Meghana V

“…OBJECTIVE: To review the chemistry, pharmacology, pharmacokinetics, safety, and efficacy of eribulin (Halaven). DATA SOURCES: A literature search (up to…”
Get full text

Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize by Giuliano, Mario, Shaikh, Anum, Lo, Hin Ching, Arpino, Grazia, De Placido, Sabino, Zhang, Xiang H, Cristofanilli, Massimo, Schiff, Rachel, Trivedi, Meghana V

“…Circulating tumor cell (CTC) clusters may represent one of the key mechanisms initiating the metastasis process. However, the series of pathophysiologic events…”
Get full text

Immunomodulator adherence in multiple myeloma patients with lower socioeconomic status: a retrospective study by Ononogbu, Onyebuchi, Akindele, Oyinkansola, Yazdanfard, Sahar, Fatima, Bilqees, Abughosh, Susan, Trivedi, Meghana V.

“…Objective Poor adherence to oral chemotherapy adversely impacts clinical outcomes and escalates overall healthcare costs. Despite barriers to medication…”
Get full text

ADGRF1 promotes tumorigenesis via the activation of STAT3 pathway in HER2+ and triple‐negative breast cancers by Abdulkareem, Noor M., Bhat, Raksha, Trivedi, Meghana V.

“…Adhesion G protein‐coupled receptors (aGPCR) regulate many cellular processes involved in cancer. ADGRF1, a class VI aGPCR, is overexpressed and/or predicts…”
Get full text

Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA by Masurkar, Prajakta P., Damgacioglu, Haluk, Deshmukh, Ashish A., Trivedi, Meghana V.

“…Background and Objective Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors improve progression-free survival when combined with endocrine therapies in…”
Get full text

Ribociclib in HR+/HER2− Advanced or Metastatic Breast Cancer Patients by Rascon, Kaitlin, Flajc, Goran, De Angelis, Carmine, Liu, Xinli, Trivedi, Meghana V., Ekinci, Ekim

“…Objective: To review the chemistry, pharmacology, pharmacokinetics, safety, and efficacy of ribociclib (LEE011, Kisqali) in hormone receptor–positive/human…”
Get full text

Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes by Chikermane, Soumya G., Sharma, Manvi, Abughosh, Susan M., Aparasu, Rajender R., Trivedi, Meghana V., Johnson, Michael L.

“…Purpose Metformin has demonstrated a chemoprotective effect in breast cancer but there is limited evidence on the effect of cumulative exposure to metformin…”
Get full text